Correlation Between Infant Bacterial and Securitas

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Infant Bacterial and Securitas at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Infant Bacterial and Securitas into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Infant Bacterial Therapeutics and Securitas AB, you can compare the effects of market volatilities on Infant Bacterial and Securitas and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Infant Bacterial with a short position of Securitas. Check out your portfolio center. Please also check ongoing floating volatility patterns of Infant Bacterial and Securitas.

Diversification Opportunities for Infant Bacterial and Securitas

-0.37
  Correlation Coefficient

Very good diversification

The 3 months correlation between Infant and Securitas is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding Infant Bacterial Therapeutics and Securitas AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Securitas AB and Infant Bacterial is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Infant Bacterial Therapeutics are associated (or correlated) with Securitas. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Securitas AB has no effect on the direction of Infant Bacterial i.e., Infant Bacterial and Securitas go up and down completely randomly.

Pair Corralation between Infant Bacterial and Securitas

Assuming the 90 days trading horizon Infant Bacterial Therapeutics is expected to generate 1.48 times more return on investment than Securitas. However, Infant Bacterial is 1.48 times more volatile than Securitas AB. It trades about 0.09 of its potential returns per unit of risk. Securitas AB is currently generating about 0.11 per unit of risk. If you would invest  3,740  in Infant Bacterial Therapeutics on August 29, 2024 and sell it today you would earn a total of  240.00  from holding Infant Bacterial Therapeutics or generate 6.42% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Infant Bacterial Therapeutics  vs.  Securitas AB

 Performance 
       Timeline  
Infant Bacterial 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Infant Bacterial Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Securitas AB 

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Securitas AB are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain fundamental indicators, Securitas sustained solid returns over the last few months and may actually be approaching a breakup point.

Infant Bacterial and Securitas Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Infant Bacterial and Securitas

The main advantage of trading using opposite Infant Bacterial and Securitas positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Infant Bacterial position performs unexpectedly, Securitas can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Securitas will offset losses from the drop in Securitas' long position.
The idea behind Infant Bacterial Therapeutics and Securitas AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Complementary Tools

Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance